Literature DB >> 11807315

Liver toxicity caused by nevirapine.

Daniel González de Requena1, Marina Núñez, Inmaculada Jiménez-Nácher, Vincent Soriano.   

Abstract

Nevirapine plasma levels were measured in 70 HIV-infected patients, 33 of whom developed transaminase elevations. Higher nevirapine levels and hepatitis C virus infection were found to be independent predictors of liver toxicity. Moreover, in individuals with chronic hepatitis C, nevirapine concentrations greater than 6 microg/ml were associated with a 92% risk of liver toxicity. Therefore, monitoring nevirapine levels, especially in individuals with chronic hepatitis C, may be warranted.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11807315     DOI： 10.1097/00002030-200201250-00020

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  29 in total

1.  Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice.

Authors:  Niamh Higgins; Alice Tseng; Nancy L Sheehan; Charles J L la Porte
Journal:  Can J Hosp Pharm       Date:  2009-11

2.  Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.

Authors:  Betty J Dong; Yu Zheng; Michael D Hughes; Adam Frymoyer; Davide Verotta; Patricia Lizak; Frederick Sawe; Judith S Currier; Shahin Lockman; Francesca T Aweeka
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

3.  Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.

Authors:  Edwin DeJesus; Peter J Piliero; Kim Summers; Mary Beth Wire; Daniel S Stein; Amanda Masterman; Yu Lou; Sherene S Min; Mark J Shelton
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 4.  Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Authors:  Karen Dahri; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  Measuring markers of liver function using a micropatterned paper device designed for blood from a fingerstick.

Authors:  Sarah J Vella; Patrick Beattie; Rebecca Cademartiri; Anna Laromaine; Andres W Martinez; Scott T Phillips; Katherine A Mirica; George M Whitesides
Journal:  Anal Chem       Date:  2012-03-02       Impact factor: 6.986

Review 6.  [Antiviral treatment regimens].

Authors:  S Esser
Journal:  Hautarzt       Date:  2006-11       Impact factor: 0.751

7.  Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.

Authors:  Jing Li; Vincent Menard; Rebekah L Benish; Richard J Jurevic; Chantal Guillemette; Mark Stoneking; Peter A Zimmerman; Rajeev K Mehlotra
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

8.  Effect of high-dose vs standard-dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial.

Authors:  Sheila Isanaka; Ferdinand Mugusi; Claudia Hawkins; Donna Spiegelman; James Okuma; Said Aboud; Chalamilla Guerino; Wafaie W Fawzi
Journal:  JAMA       Date:  2012-10-17       Impact factor: 56.272

Review 9.  Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century.

Authors:  Vincent Lo Re; Jay R Kostman; Valerianna K Amorosa
Journal:  Clin Liver Dis       Date:  2008-08       Impact factor: 6.126

Review 10.  Financial burden of health services for people with HIV/AIDS in India.

Authors:  N Kumarasamy; K K Venkatesh; K H Mayer; Kenneth Freedberg
Journal:  Indian J Med Res       Date:  2007-12       Impact factor: 2.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.